Skye Bioscience CEO Punit Dhillon Receives 1,090,000-Share Award

What Happened
Skye Bioscience CEO Punit Dhillon was granted 1,090,000 restricted stock units (RSUs) on 2026-08-07. The award was reported as an acquisition at $0.00 per unit (code A); each RSU represents a contingent right to one share of common stock. The filing does not state a dollar value or the total number of shares Mr. Dhillon owns after this grant.

Key Details

• Transaction date: 2026-08-07 (reported same day). Transaction type: Award (A). Price reported: $0.00 per RSU.
• Award amount: 1,090,000 RSUs; each RSU = one contingent share (Footnote F2).
• Vesting: RSUs will vest on August 31, 2027 contingent on continued employment through that date OR on certain types of termination by the Company (not for Cause, Death or Disability), provided the executive signs and does not revoke the release agreement (Footnote F1).
• Shares owned after transaction: not disclosed in the filing.
• Timeliness: filing covers the grant dated and reported 2026-08-07 (no late filing indicated).

Context
This is a compensation/retention award rather than an open-market purchase or sale; such grants are common for executives and do not by themselves signal immediate buying or selling interest in the market. The RSUs are contingent and subject to vesting/forfeiture conditions, so they only convert to actual shares if vesting conditions are met.